39 news items
I-Mab Enters Clinical Collaboration With Bristol Myers Squibb To Evaluate Claudin 18.2 x 4-1BB Bispecific Antibody Givastomig Combination; No Terms Disclosed
BMY
IMAB
5 Jun 24
The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by I
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
BMY
4 Jun 24
to investigator's choice of lenvatinib or sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). Results from
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY
3 Jun 24
the patients and investigators participating in the CheckMate -816, CheckMate -77T and CheckMate -9LA clinical trials
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
BMY
1 Jun 24
and investigators involved in the KRYSTAL-12 clinical trial.
This study was funded by Mirati Therapeutics
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
BMY
30 May 24
," said Michael Wang, M.D., lead investigator and Puddin Clarke Endowed Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine
tvpwbc75f sc6i1xbrwpea13lbgnskusqob3ee464
BMY
CCCC
ONCY
28 May 24
of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial. "I am enthusiastic about the expansion of this cohort
976b nqxqr9wdazp
BMY
CCCC
ONCY
28 May 24
of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial. "I am enthusiastic about the expansion
ettgmvy3wf833ghiofyigm
BMY
23 May 24
(ASCO) Annual Meeting and the European Hematology Association (EHA) 2024 Hybrid Congress. Data from more than 130 company-sponsored studies, investigator
68e2l88k2q5qg7a9zgu7ab44nqgxcvu9kakbbz9hndn0c
BMY
16 May 24
," said April Armstrong, MD, MPH, clinical investigator in the POETYK PSO clinical trial program and professor and chief of dermatology at the University
wlr9vav1uqwp4r86jn7wmhru7rg737s6
BMY
15 May 24
prognosis," said M. Lia Palomba, M.D., TRANSCEND investigator and lymphoma and cell therapy specialist, Memorial Sloan Kettering Cancer Center. "The FDA
4dgph3d9dbmyic6kg11p5zpqsshbymtpgx fy3sbh4b
BMY
10 May 24
development efforts in this setting. We want to thank the patients, families and investigators for their contributions to this important research
bicgtjhoqf7usj1jxoz7nbhj2zcxuhhdu9m5y7a4aul4egwtcu9naa
BMY
10 May 24
future drug development efforts in this setting. We want to thank the patients, families and investigators for their contributions to this important
v6laxf8bbjmyzhrcfcbzplc6qg4d41eo6yr 9x
BMY
26 Apr 24
squamous cell carcinoma.
Bristol Myers Squibb thanks the patients and investigators involved
up3m8e8k w687na2y
BMY
25 Apr 24
to investigator's